سعر ميو جريل بلاس 75/75مجم 30 قرص 2025

Myogrel plus 75/75 mg film-coated tablets (30 tablets; Adwia, Egypt): fixed-dose combination of clopidogrel 75 mg and acetylsalicylic acid 75 mg, a dual antiplatelet therapy.

• Secondary prevention of atherothrombotic events: continuation therapy in non-ST-elevation acute coronary syndrome (unstable angina or non-Q-wave MI), including after PCI with stentPopulation: Adults already taking clopidogrel and aspirinEuropean Medicines Agency (EMA)
• Secondary prevention of atherothrombotic events: continuation therapy in ST-elevation acute myocardial infarction (PCI or medically treated, thrombolysis-eligible)Population: Adults already taking clopidogrel and aspirinEuropean Medicines Agency (EMA)

• Bleeding is the most common reaction (mostly in the first month); other reactions include haematoma, epistaxis, gastrointestinal haemorrhage, diarrhoea, abdominal pain, dyspepsia and bruising.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to the active substances or excipients; severe hepatic impairment; active pathological bleeding (peptic ulcer, intracranial haemorrhage); NSAID hypersensitivity and asthma/rhinitis/nasal polyps syndrome; mastocytosis; severe renal impairment; third trimester of pregnancy.International label, same formulation · European Medicines Agency (EMA)

• Bleeding risk: use with caution with trauma, surgery, other NSAIDs, heparin, GP IIb/IIIa inhibitors, SSRIs, thrombolytics; oral anticoagulants not recommended; stop 7 days before elective surgery if antiplatelet therapy must be interrupted.International label, same formulation · European Medicines Agency (EMA)
• Thrombotic thrombocytopenic purpura and acquired haemophilia reported with clopidogrel; poor CYP2C19 metabolisers form less active metabolite; avoid strong/moderate CYP2C19 inhibitors (e.g. omeprazole, esomeprazole).International label, same formulation · European Medicines Agency (EMA)

• Oral anticoagulantsNot recommended; may increase bleeding intensity.European Medicines Agency (EMA)
• Strong or moderate CYP2C19 inhibitors (omeprazole, esomeprazole, fluvoxamine, fluoxetine, voriconazole, fluconazole)Reduced levels of clopidogrel active metabolite; concomitant use discouraged.European Medicines Agency (EMA)
• NSAIDs, SSRIs, heparin, GP IIb/IIIa inhibitors, thrombolyticsIncreased bleeding risk; use with caution.European Medicines Agency (EMA)

• No clinical data with the combination; should not be used in the first two trimesters unless the clinical condition requires clopidogrel/ASA; contraindicated in the third trimester because of ASA.International label, same formulation · European Medicines Agency (EMA)
• Clopidogrel is excreted in animal milk and ASA in limited amounts in human milk; breast-feeding should be discontinued during treatment.International label, same formulation · European Medicines Agency (EMA)

• Clopidogrel: Prodrug whose active metabolite irreversibly binds the platelet P2Y12 ADP receptor, inhibiting ADP-induced platelet aggregation for the platelet lifespan.
• Acetylsalicylic acid: Irreversibly inhibits platelet cyclooxygenase, reducing thromboxane A2 generation and platelet aggregation.